Navigation Links
Study details how protein made by HPV teams up on and thwarts protective human protein
Date:1/11/2011

BETHESDA, Md., Jan. 11, 2011 An international team of researchers is reporting that it has uncovered new information about human papillomavirus that one day may aid in the development of drugs to eliminate the cervical-cancer-causing infection.

Led by researcher Per Jemth of Uppsala University in Sweden, the collaborators from four institutions detail in the Journal of Biological Chemistry how an offensive protein generated by the sexually transmitted virus handicaps a defensive protein made by the human body.

Co-author Neil Ferguson, a biophysicist at University College Dublin, says: "It has proved difficult to stem the proliferation of many viruses using conventional drug discovery. Inhibitors of protein-protein interactions, as in HPV's case, are potentially potent ways to perturb viral infections."

There are almost 200 strains of HPV, dozens of which are transmitted through genital contact, and about half of sexually active people have had one or more infections.

The immune system eliminates the virus within two years in about 90 percent of cases, according to the Centers for Disease Control and Prevention in Atlanta, but it lingers for many years in a minority of cases. Some strains result in no visible symptoms, others cause genital warts and still others cause cancer.

"Infection by high-risk human papillomaviruses is causing as many as half a million cases of cervical cancer and more than 200,000 deaths among women per year, making it one of the most common forms of cancer," Jemth emphasized.

For the virus to replicate, it has to interfere with the body's natural inclination to kill infected cells.

What is known as "programmed cell death," or the destruction of sick cells, ordinarily is carried out by several human proteins. However, when HPV is present, the virus sends out two of its own assassin proteins, known as E6 and E7, to stop the defensive human proteins in their tracks.

"Why is the virus causing cancer? In rare cases, the HPV infection is not cleared by the immune system and persists for decades. The virus' release of E6 and E7 proteins then increases the risk of deterioration to cancer by causing cell proliferation and preventing programmed cell death," explains Jemth. "If the cell dies, the virus will die along with it. So, the virus sends out these gunmen to assassinate proteins made by the body -- a hostile takeover, if you like."

In its study, Jemth's team offers a detailed look at how one human protein in particular, SAP97, is targeted by HPV assassin E6.

"To develop antivirals that prevent protein-protein interactions, in this case those of E6 and human proteins, it is necessary to first understand the biomolecular interactions required for virus viability and, where relevant, exploit these insights," says Ferguson.

So, the team used different techniques to visualize the attack or, rather, how HPV's E6 and man's SAP97 bind to each other.

"We studied how fast E6 is latching onto SAP97, how fast it is coming off, how strongly it holds onto SAP97, and what happens to the shape of SAP97 as E6 is attached to it," says Celestine Chi, the first author of the paper.

It turns out that there are three places on SAP97 where HPV's E6 can latch on, he says, which bogs down the human protein so that it cannot carry out its normal function.

In fact, the team reports, three E6 molecules can attach to one SAP97 molecule simultaneously essentially teaming up on the protein.

There currently are two vaccines that prevent HPV infection on the market, Cervarix and Gardasil, but they do nothing for those people who already are infected.

"Fundamental research on HPV is, therefore, still necessary to discover new routes to cure infection," Jemth says, which is why the team intends to continue its investigation and now has its crosshairs on HPV's E7 protein.

Ferguson adds: "The team's work represents an important step forward in understanding HPV biology and has important implications for therapeutic strategies. What was nice about this collaboration is that multiple laboratories worked synergistically such that the scope of the research and strength of the conclusions were significantly increased."


'/>"/>

Contact: Angela Hopp
ahopp@asbmb.org
301-634-7389
American Society for Biochemistry and Molecular Biology
Source:Eurekalert  

Related medicine news :

1. Private Rooms Cut Infection Risk in the ICU: Study
2. Closely Spaced Pregnancies Might Up Autism Risk: Study
3. U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study
4. Case Western Reserve University School of Medicine launches the National Childrens Study
5. Spanish heart risk study challenges image of healthy Mediterranean diet and lifestyle
6. Study Refutes Myth That Eating Disorders Affect Whites Only
7. Many Survivors of World Trade Center Attacks Suffered PTSD: Study
8. Study shows promise for new drug to treat Fragile X
9. Age Takes Toll on Facial Bones, Study Finds
10. Circumcision Helps Cut HPV Transmission Rate, Study Finds
11. Liver disease a possible predictor of stroke: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study details how protein made by HPV teams up on and thwarts protective human protein
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
Breaking Medicine Technology: